Global Ampoules & Syringes Market Reaches USD 12 Bn in 2026, Driven by Rising Demand for Injectable Drugs and Vaccination Programs - Coherent Market Insights

Advancements in Prefilled Syringes and Safety-Engineered Drug Delivery Systems to Drive Global Ampoules & Syringes Market to USD 19.3 Bn by 2033 at 7.2% CAGR – Coherent Market Insights

Ampoules are vial that is used to store solution or powder which is prepared into a solution for the intramuscular or intravenous injection. It is made up of plastic or glass and comes in a sealed form in order to prevent microbial contamination. PVC, polyethylene, and polypropylene are some of the type of the plastic used to produce ampoules. The syringe is a medical device that has a hollow needle attached to it that pierce the skin in order to administer the drug into the body. The needle is made up of plastic and disposable product in order to reduce the risk of reuse. Traditionally, it was produced with the metal or glass and require sterilization and cleaning. Plastic is a result of advancements in technology in order to enhance the medical facility.

The global ampoules & syringes market is expected to surpass USD 19.3 Bn in terms of value by the end of 2033.

Drivers

Increasing demand for prefilled syringes that ensure precise delivery of the drug is expected to augment growth of the ampoules & syringes market. These syringes can be stored easily due to excellent property of crack resistance and covering which enable easy transport and storage. These syringes are produced from a polymer such as thus offering durability in terms of physical damage. Therefore, the rising demand for prefilled syringes is expected to foster the market growth of ampoules & syringes.

• Rising Demand for Biologics and GLP-1 Therapies

The growing use of injectable biologics and GLP-1 medicines for diabetes, obesity, and other chronic conditions is increasing demand for high-quality glass syringes and injectable-drug packaging. In January 2026, BD announced a USD 110 million investment to establish BD Neopak glass prefillable-syringe production in Nebraska, specifically supporting biologic and GLP-1 drug delivery. SCHOTT Pharma also reported that demand for prefillable glass syringes, particularly for GLP-1 products, remained high in fiscal Q1 2026. (Source: BD Newsroom, Schott Pharma)

Market Opportunities

Plastic ampoules are gaining traction in the market especially polyethylene ampoules due to their excellent chemical and mechanical property is expected to augment the market growth. The plastic-based ampoules offer easy storage and transportation and crack resistant properties. This property of the polyethylene ampoules is projected to fuel the market growth of the ampoules & syringes over the forecast period.

• Growing Preference for Prefilled Syringes and At-Home Treatment

Pharmaceutical companies are increasingly adopting prefilled syringes that can be integrated with autoinjectors, supporting convenient and consistent drug administration in hospitals and home-care settings. For instance, in January 2026, BD and Ypsomed expanded their partnership to develop a 5.5 mL glass prefillable syringe compatible with the YpsoMate 5.5 autoinjector, with samples scheduled for feasibility studies from mid-2026. This development addresses the need for larger-volume biologic self-administration. (Source: BD Newsroom)

• Expansion of Vaccination and Routine Immunization Programs

Large-scale childhood, adult, and seasonal vaccination programs continue to generate recurring demand for disposable syringes, needles, ampoules, and injectable-vaccine packaging. For instance, in July 2026, WHO reported that approximately 110 million infants received three DTP vaccine doses in 2025, while 13.5 million children remained completely unvaccinated, indicating substantial continuing demand and coverage-expansion potential. The UK’s 2026 routine schedule also includes multiple injectable vaccines for infants, adolescents, and older adults. (Source: WHO)

Global Ampoules & Syringes Market: Recent Developments

• In June 2026, Alkem Laboratories launched semaglutide in single-shot pre-filled syringes in India, becoming the country’s first company to offer this delivery format. Available in multiple dose strengths at prices starting from INR 350, the DCGI-approved product supports treatment of Type 2 diabetes and obesity alongside diet and exercise. The ready-to-use format expands patient choice, improves convenience, and lowers entry barriers to semaglutide therapy across India’s rapidly expanding metabolic-care market. (Source: Alkem Laboratories)
• In January 2026, Terumo launched the SurTract Safety Syringe in the U.S. The syringe uses SafeR passive-safety technology, which automatically retracts the needle into the plunger after injection. Its low-dead-space design reduces medication waste, while the absence of an external safety sheath lowers plastic waste and needle-stick risks. (Source: Terumo)
• In January 2026, West Pharmaceutical Services, Inc. announced the global commercial availability of its Synchrony S1 prefillable syringe system. The portfolio includes 1 mL-long and 2.25 mL staked-needle syringes for biologics, along with 1 mL standard staked-needle and Luer-lock formats for vaccines, supported by high-performance plungers and integrated closure components. (Source: West Pharmaceutical Services, Inc.)
• In May 2026, B. Braun launched Rocuronium Bromide Injection in a 50 mg/5 mL single-dose Luer-lock prefilled syringe. The company described it as the first FDA-approved room-temperature-stable prefilled syringe for the drug. Its 24-month shelf life and elimination of refrigerated transportation can simplify hospital storage, distribution, inventory management, and emergency preparation. (Source: B. Braun USA)

Market Restraints

Product recall due to damage to the product is expected to restrict market growth. In the recent past years, there has been an increase in the product recalls recorded for glass ampoules & syringes because of glass breakages. The recall was also due to other issues such as leachable. For instance, there was a recall of Eprex pre-fillable syringes due to leachable from the prefilled syringe rubber plunger. Hence, rising cases of product recall is expected to hinder the market growth.

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/ampoules-and-syringes-market-4752

Key Takeaways

• The global ampoules & syringes market was valued at US$ 12 Bn in 2026 and is forecast to reach a value of US$ 19.3 Bn by 2033 at a CAGR of 7.2% between 2026 and 2033.
• Based on product type, syringes segment dominates the market with share of 68.4 % in 2026. The increasing use of injectable biologics and GLP-1 medicines for diabetes and obesity is driving demand for advanced prefilled glass syringes. In January 2026, BD announced a USD 110 million investment to expand U.S. production of prefillable syringes for biologic and GLP-1 drug delivery.
• The glass segment and is expected to witness a market share of 69.2% over the forecast period.  The glass segment dominates because Type I borosilicate glass provides chemical resistance, strong barrier protection, transparency, sterilization compatibility, and minimal drug interaction, making it suitable for biologics and GLP-1 therapies. In January 2026, BD announced a USD 110 million investment to expand Neopak glass prefillable syringe production capacity in Nebraska.

Market Trends

• Development of Large-Volume Syringes for High-Viscosity Drugs

The growing number of concentrated biologics is creating demand for larger syringe formats capable of delivering high-volume and high-viscosity formulations through autoinjectors. In January 2026, BD and Ypsomed expanded their partnership to develop a 5.5 mL BD Neopak XtraFlow glass prefillable syringe compatible with the YpsoMate 5.5 autoinjector. Feasibility-study samples were scheduled to become available in mid-2026. (Source: BD Newsroom)

• Integration of Syringes with Autoinjectors and Home-Treatment Systems

Prefillable syringes are increasingly being designed as components of autoinjectors, wearable injectors, and other patient-controlled delivery systems. At Pharmapack 2026, BD showcased syringe and delivery technologies supporting subcutaneous administration of GLP-1 therapies and high-dose biologics. Gerresheimer similarly emphasized that the increasing use of biologics and the transition toward home treatment are driving demand for integrated drug-containment and delivery solutions.

• Increasing Focus on Digital Traceability and Connected Drug Delivery

Syringe manufacturers are introducing digital identification technologies to improve product traceability, fill-finish quality control, and batch-level monitoring. In January 2026, BD presented its iDFill Individual Prefillable Syringe Identification solution, which is being developed to provide unique identification for individual primary containers. Gerresheimer also introduced Gx InMonit, a connected autoinjector add-on that confirms successful injections and transmits adherence data through cloud connectivity. Both technologies indicate the growing integration of digital capabilities into injectable-delivery systems. (Source: BD Newsroom)

• Premiumization of Glass-Based Injectable Packaging

Demand is gradually moving toward higher-quality glass containers offering tighter dimensional tolerances, improved container-closure integrity, lower particle levels, and enhanced compatibility with sensitive formulations. In the first quarter of 2026, SCHOTT Pharma’s drug-containment segment which includes glass ampoules, vials, and cartridges recorded 9.4% constant-currency revenue growth. This indicates continued demand for premium glass packaging, although current innovation and investment are increasingly concentrated in sterile and high-value injectable formats. (Source: Schott Pharma)

• Localization and Expansion of Advanced Syringe Manufacturing

Manufacturers are regionalizing pharmaceutical-packaging production to improve supply-chain resilience, shorten lead times, and support domestic biologics manufacturing. In January 2026, BD announced a USD 110 million investment in Columbus, Nebraska, including USD 100 million for BD Neopak glass prefillable-syringe production and USD 10 million for cannula-manufacturing improvements. Commercial supply from the expanded syringe capacity was expected to begin in mid-2026. (Source: BD Newsroom)

Competitive Section

• Company Names 
  • Schott AG
  • Gerresheimer AG
  • Becton, Dickinson, and Company 
  • West Pharmaceutical Services, Inc.
  • Nipro Corporation
  • Vetter Pharma International GmbH 
  • Stevanato Group
  • TOPAS Advanced Polymers
  • JSR CORPORATION.
  • Baxter International Inc.
  • Terumo Corporation
  • B. Braun Melsungen AG
  • Unilife Corporation
  • Ypsomed Holding AG
  • Medtronic
  • Zeon Corporation